1887

Abstract

Purpose. Human papillomavirus (HPV) infection in women is known to promote the development of cervical neoplasia. Specific HPV genotypes are more highly associated with disease, and therefore detection and genotyping of HPV infection is critical for preventing and effectively treating cervical cancer. Consequently, various assays using diverse technologies have been developed to detect HPV genotype. Recently the OmniPlex-HPV and GeneFinder HPV methods, based on PCR and Luminex xMAP liquid bead microarray technologies, were developed for the detection of 40 and 32 HPV genotypes, respectively. The purpose of this study was to compare the clinical performance of OmniPlex-HPV and GeneFinder HPV.

Methodology. The study included 300 cytology-confirmed cervical swab specimens. In cases where there was a discrepancy between the two assay results, type-specific direct sequencing was performed.

Result. We found a high overall agreement between OmniPlex-HPV and GeneFinder HPV for detecting the presence or absence of high-risk HPV (HR HPV) (90.7 %, κ=0.810). However, OmniPlex-HPV showed greater sensitivity than GeneFinder HPV in the identification of multiple genotype-infected samples. Specifically, diagnostic sensitivities for HR HPV positivity in high-grade squamous intra-epithelial lesions (HSIL) were 100.0 % for OmniPlex-HPV and 96.8 % for GeneFinder HPV.

Conclusions. Our results suggest that OmniPlex-HPV and GeneFinder HPV are highly comparable for the detection and genotyping of HPV, but OmniPlex-HPV displays greater accuracy in cases of multiple HPV infection.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000798
2018-07-17
2019-12-06
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/9/1279.html?itemId=/content/journal/jmm/10.1099/jmm.0.000798&mimeType=html&fmt=ahah

References

  1. Molijn A, Kleter B, Quint W, Doorn L-Jvan. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005;32:43–51 [CrossRef]
    [Google Scholar]
  2. Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol 2014;26:13–21 [CrossRef][PubMed]
    [Google Scholar]
  3. Viarisio D, Gissmann L, Tommasino M. Human papillomaviruses and carcinogenesis: well-established and novel models. Curr Opin Virol 2017;26:56–62 [CrossRef][PubMed]
    [Google Scholar]
  4. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1–17 [CrossRef][PubMed]
    [Google Scholar]
  5. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927–935 [CrossRef][PubMed]
    [Google Scholar]
  6. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–527 [CrossRef][PubMed]
    [Google Scholar]
  7. Lee DH, Hwang NR, Lim MC, Yoo CW, Joo J et al. Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and hybrid capture 2. Ann Clin Biochem 2016;53:561–567 [CrossRef][PubMed]
    [Google Scholar]
  8. Ko K, Kwon MJ, Lee EH, Woo HY, Park H. Comparison of GeneFinder human papillomavirus (HPV) liquid beads microarray PCR kit and hybrid capture 2 assay for detection of HPV infection. J Clin Lab Anal 2017;31:e22025 [CrossRef][PubMed]
    [Google Scholar]
  9. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol 2009;10:321–322 [CrossRef][PubMed]
    [Google Scholar]
  10. Lee SH, Vigliotti JS, Vigliotti VS, Jones W. From human papillomavirus (HPV) detection to cervical cancer prevention in clinical practice. Cancers 2014;6:2072–2099 [CrossRef][PubMed]
    [Google Scholar]
  11. Asato T, Maehama T, Nagai Y, Kanazawa K, Uezato H et al. A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis 2004;189:1829–1832 [CrossRef][PubMed]
    [Google Scholar]
  12. Chung MY, Kim YW, Bae SM, Kwon EH, Chaturvedi PK et al. Development of a bead-based multiplex genotyping method for diagnostic characterization of HPV infection. PLoS One 2012;7:e32259 [CrossRef][PubMed]
    [Google Scholar]
  13. Lee HP, Cho W, Bae JM, Shin JY, Shin SK et al. Comparison of the clinical performance of restriction fragment mass polymorphism (RFMP) and Roche linear array HPV test assays for HPV detection and genotyping. J Clin Virol 2013;57:130–135 [CrossRef][PubMed]
    [Google Scholar]
  14. Carozzi F, Bisanzi S, Sani C, Zappa M, Cecchini S et al. Agreement between the AMPLICOR human papillomavirus test and the hybrid capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J Clin Microbiol 2007;45:364–369 [CrossRef][PubMed]
    [Google Scholar]
  15. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357–361[PubMed]
    [Google Scholar]
  16. Lee HP, Kim SO, Hwang TS, Bae JM, Kim SN et al. Analytical and clinical performances of a restriction fragment mass polymorphism assay for detection and genotyping of a wide spectrum of human papillomaviruses. J Med Virol 2011;83:471–482 [CrossRef][PubMed]
    [Google Scholar]
  17. Yoon YA, Kim BH, Heo SH, Kim HJ, Choi YJ. Comparative evaluation of the Omniplex-HPV and RFMP HPV PapilloTyper for detecting human papillomavirus genotypes in cervical specimens. Arch Virol 2018;163:969–976 [CrossRef][PubMed]
    [Google Scholar]
  18. Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 2013;108:908–913 [CrossRef][PubMed]
    [Google Scholar]
  19. Choi J, Park Y, Lee EH, Kim S, Kim JH et al. Detection and genotyping of human papillomavirus by five assays according to cytologic results. J Virol Methods 2013;187:79–84 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000798
Loading
/content/journal/jmm/10.1099/jmm.0.000798
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error